title: Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?
authors.affiliation: Department of Pediatric Hematology-Oncology, Agia Sofia Children's Hospital, Athens, Greece. vpapadak@otenet.gr
authors.forename: Vassilios
authors.initials: V
authors.lastname: Papadakis
authors.forename: Dimitri
authors.initials: D
authors.lastname: Karakasis
authors.forename: Petros P
authors.initials: PP
authors.lastname: Sfikakis
authors.forename: Ioannis
authors.initials: I
authors.lastname: Baltadakis
authors.forename: John
authors.initials: J
authors.lastname: Apostolidis
authors.forename: Kostas
authors.initials: K
authors.lastname: Evangelou
authors.forename: Vassilis G
authors.initials: VG
authors.lastname: Gorgoulis
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Harhalakis
mesh_terms: D001549:Benzamides; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications; D015477:Leukemia, Myelomonocytic, Chronic / Q000150:complications; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects; D010879:Piperazines; D011743:Pyrimidines; D012595:Scleroderma, Systemic / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate